Telomir Pharmaceuticals, Inc. financial data

Symbol
TELO on Nasdaq
Location
Miami, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 477% % 99%
Debt-to-equity 26% % -24%
Return On Equity -567% % 47%
Return On Assets -448% % 44%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34,380,971 shares 16%
Common Stock, Shares, Outstanding 33,830,971 shares 14%
Entity Public Float $113,300,000 USD
Weighted Average Number of Shares Outstanding, Basic 32,398,906 shares 9.4%
Weighted Average Number of Shares Outstanding, Diluted 32,398,906 shares 9.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,348,443 USD -40%
General and Administrative Expense $9,901,161 USD 34%
Operating Income (Loss) $2,187,872 USD 14%
Nonoperating Income (Expense) $15,445 USD
Net Income (Loss) Attributable to Parent $11,250,385 USD 51%
Earnings Per Share, Basic 1 USD/shares 321%
Earnings Per Share, Diluted 1 USD/shares 321%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $754,323 USD
Assets, Current $7,402,117 USD 610%
Assets $7,402,117 USD 610%
Liabilities, Current $422,807 USD -30%
Liabilities $422,807 USD -30%
Retained Earnings (Accumulated Deficit) $38,948,870 USD -41%
Stockholders' Equity Attributable to Parent $6,979,310 USD 1479%
Liabilities and Equity $7,402,117 USD 610%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $863,132 USD 55%
Net Cash Provided by (Used in) Financing Activities $5,212,498 USD 608%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 33,830,971 shares 14%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $863,132 USD -126%
Deferred Tax Assets, Valuation Allowance $7,182,483 USD 749%
Deferred Tax Assets, Gross $7,182,483 USD 749%
Deferred Tax Assets, Operating Loss Carryforwards $4,427,679 USD 1435%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Additional Paid in Capital $45,928,180 USD 63%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $1,400,000 USD
Interest Expense $4,338,543 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares